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Abstract
Background: The number of Human Immunodeficiency Virus (HIV) infected people eligible for initiation on
antiretroviral Therapy (ART) is increasing. ART programmatic success requires that patients who are taking ART
remain on treatment and are followed up regularly. This study investigated factors associated with being lost to
follow-up, in a cohort of patients enrolled in a pharmacovigilance study in South Africa.
Methods: This was a retrospective observational cohort study performed at one of the Medunsa National
Pharmacovigilance Centre’s (MNPC) ART sentinel surveillance sites. Loss to Follow-up (LTFU) was defined as “a patient
who had been followed up at the sentinel site, who had not had contact with the health facility for 180 days or more
since their last recorded expected date of return or if there were 180 days or more between the expected date of
return and the next clinic visit”.
Results: Out of 595 patients, 65.5 % (n = 390) were female and 23.4 % (n = 139) were LTFU. The median time
on ART before LTFU was 21.5 months (interquartile range: 12.9 – 34.7 months). The incidence rate of LTFU
was 103 per 1000 person-years in the first year on ART and increased to 405 per 1000 person-years in the
eighth year of taking ART. Factors associated with becoming LTFU included not having a committed partner
(Adjusted Hazard Ratio (aHR): 2.9, 95 % Confidence Interval (CI):1.19-6.97, p = 0.019), being self-employed (aHR: 13.9,
95 % CI:2.81 - 69.06, p = 0.001), baseline CD4 count > 200 cells/ml (aHR: 3.8, 95 % CI: 1.85-7.85, p < 0.001), detectable last
known Viral Load (VL) (aHR: 3.6, 95 % CI:1.98 - 6.52, p < 0.001) and a last known World Health Organisation clinical stage
three or four (aHR: 2.0, 95 % CI:1.22-3.27, p = 0.006). Patients that previously had an ART adverse event had a lower risk
(aHR: 0.6, 95 % CI: 0.38 - 0.99, p = 0.044) of becoming LTFU than those that had not.
Conclusion: The incidence rate of LTFU increases with additional years on ART. Intensified measures to improve
patient retention on ART must be prioritised with increasing patient time on ART and in patients that are at increased
risk of becoming lost to follow-up.
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Background
Human immunodeficiency Virus (HIV) is a public health
challenge worldwide. In 2013, the United Nations pro-
gram on HIV/AIDS (UNAIDS) reported that there were
an estimated 35.3 million people living with HIV globally
[1]. The most affected region is Sub Saharan Africa,
which accounted for close to 70 % of all new HIV infec-
tions in 2013 [2]. South Africa has the highest number
of people living with HIV (6.3 million) [3], and also has
the largest HIV treatment programme, with 1.8 million
persons reported to have been initiated on antiretroviral
treatment (ART) since the commencement of the treat-
ment programme [4]. Though there has been an increase
in the scale up of access to ART in South Africa, there is
also an increasing number of people that are becoming
eligible for ART as new ART eligibility criteria are being
introduced [4] and newly acquired HIV infections con-
tinue to be reported in the population [1].
ART, which continues to be the mainstay of HIV man-
agement, acts to prevent HIV multiplication and reduces
the viral load in the blood, resulting in improved im-
mune function of an HIV-infected person and a decrease
in the risk of transmitting the virus [2, 5]. The acceler-
ated scale up of access to ART has led to a decline in
HIV related morbidity, mortality and new HIV infections
globally [1, 6]. As sustainability is becoming a priority in
the response to the AIDS epidemic, high loss to follow-
up (LTFU) rates have the potential to reverse gains that
have been achieved thus far.
There is evidence that interrupting ART leads to inferior
clinical outcomes and higher risks of opportunistic compli-
cations and death in patients [7]. However, studies in
sub-Saharan Africa have shown that less than two-thirds of
patients initiated on ART are on treatment 2 years after
ART initiation [8], and a systemic review showed a 70 %
24 month retention rate and a 65 % 36 month patient
retention rate [9]. Furthermore, it has been shown that
there is an increasing cumulative incidence of LTFU with
each year of taking ART in South Africa [10]. The South
African National Strategic Plan on HIV, Tuberculosis
and Sexually Transmitted Infections (2012–2016) has a
goal not only to initiate at least 80 % of eligible patients
on ART, but for at least 70 % of patients that are initi-
ated on ART to be alive and on treatment 5 years after
initiation [11].
Though investigations have been done around factors
that possibly minimise the rates of LTFU [8, 12–16], few
studies have been done to determine factors associated
with LTFU in South Africa [17–21]. Coupled with the
challenge of limited research around LTFU, there are
also several definitions of LTFU which vary across differ-
ent programs and studies. This means research findings
around LTFU may not, necessarily, remain the same if a
different definition of LTFU is applied. A study on the
impact of LTFU definitions recommended that the
definition of LTFU should be based on the study out-
come of interest, available encounter data and the cohort
visit schedule [22].
The objectives of this study were to determine the
incidence of, and factors associated with, LTFU in a
cohort of patients enrolled in a Pharmacovigilance (PV)
sentinel site in Gauteng province, South Africa.
Methods
Study setting
Tshepang clinic is an ART clinic located at Dr. George
Mukhari Hospital, one of the largest academic hospitals in
Gauteng province. The clinic is one of three functional
pilot sites of the Medunsa National Pharmacovigilance
Centre’s (MNPC) ART surveillance cohort study. The
MNPC was opened in September 2004 as a National
Department of Health (NDoH) initiative at the same time
when ART became available in the South African public
health sector. The Centre operates a structured ART
surveillance program which monitors and assesses the
impact and safety profile of ART medicines in a cohort
of patients [23].
One of the Centre’s main objectives is to determine
and reduce morbidity and mortality related to ART drug
use in HIV-infected patients [24]. From 2004, more than
1000 patients were enrolled into the Medunsa National
Pharmacovigilance cohort in Tshepang clinic. In a report
submitted to the NDoH in 2011, the MNPC noted that
a large number of patients were LTFU at its sentinel
sites, but the incidence and risk factors of LTFU were
not known.
Study population and sampling
HIV-infected patients who were more than 14 years of
age and were on ART were selected to participate in this
study using a systematic random sampling method at
the PV sentinel site. Patients that signed informed
consent were enrolled into the PV study. A retrospective
case report form (CRF) was completed and submitted
for data capturing after which patients were followed up
prospectively with each clinic visit.
Study design
This was a retrospective observational cohort study.
Secondary data analysis of patients enrolled into the
Medunsa PV cohort and being followed up at Tshepang
clinic was performed. Chart reviews were done to
include other variables that were not included on the
standard PV CRF as well as to gather any missing infor-
mation in the PV database.
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Definitions
The working definition of LTFU in South Africa is
“when 3 calendar months have passed without the
patient having drugs in hand” [25]. LTFU, as defined by
Chi et al. (2011), is when a patient has had 180 days or
more since the last clinic visit. This definition was found
to minimise misclassifications of patients and was rec-
ommended for use to allow for comparison of programs
[26]. In our study, a patient was classified as LTFU if the
patient had been followed up at least once after ART
initiation, but had not had contact with the clinic for
180 days or more since their last recorded expected re-
turn date, or if there were 180 days or more between the
expected date of return and the next clinic visit. Patients
that were not LTFU were referred to as patients that are
“in care” in this article. A maximum of 3 months
(90 days) of treatment can be dispensed to a patient at
one time in Tshepang clinic. Therefore, according to our
definition, patients that were classified as LTFU had not
had treatment for 3 (if three months of treatment had
been dispensed at the last clinic visit) to under 6 months
(if less than 1 month of treatment had been dispensed to
the patient at the last visit).
Virological suppression refers to an individual who has
a fully suppressed viral load (VL), as evidenced by a VL
level that is undetectable or a VL that is below 50
copies/ml.
A person who has a partner includes people who are
married or are cohabiting with a life partner. A person
without a partner includes people who are single, sepa-
rated, divorced or who are a widow or widower and not
living with or married to a partner.
An adverse event is “any untoward medical occurrence
that may appear during treatment with a pharmaceutical
product, but which does not necessarily have a causal
relationship with the treatment” [20].
WHO Stages three and four in adults and adolescents
(ages of 15 years or more) are stages that indicate
advanced HIV symptoms and Severe advanced HIV
symptoms, respectively, in people who have been found
to be HIV infected, as illustrated by the presence of any
clinical conditions or symptoms that are classified as
WHO stage three or WHO stage four conditions [27].
Patients were classified as dead using the South African
Home affairs website which identifies death status at the
date and time of the enquiry. Retrospective information
cannot be retrieved on the website therefore date of death
could not be ascertained.
Patients that are clinically stable on ART and virolo-
gically suppressed are “down referred” to primary care
facilities that are nearest to them, usually within the
same sub-district, for patient follow-up [25].
Transferred patients are those patients that for any
reason request to be followed up at a different clinic,
often outside of the sub-district in which they were
being followed up. They are given a transfer letter for
further follow-up at their requested facility irrespective
of whether they are clinically or virologically, well or
unwell [25].
Statistical analyses
Statistical analysis was done in STATA Corp version 12
[28]. Patients that were LTFU, transferred out, who had
died and those who are still in care at Tshepang clinic
were identified and described. Further analysis was then
focused on the LTFU outcome. Patients’ data was cen-
sored on the 30th June 2012 and patients who were trans-
ferred out were considered to be still in care at the time of
censoring. Patients who had missing files, an unknown
initiation date or unknown last visit date or whose out-
come could not be determined were not included in the
analysis.
Medians, means and proportions were used to describe
demographic characteristics and baseline characteristics.
We compared the differences in variables measured at
baseline and after ART initiation using chi2 for pro-
portions and non-parametric statistics for data that was
continuous and not normally distributed. Univariate com-
parisons between proportions of patients that were classi-
fied as LTFU and those not classified as LTFU was done
using Kaplan-Meier survival curves with a log-rank test
for equality of survival curves. Sex, age and factors that
had a p-value less than 0.20 in bivariate analysis were
included in the multivariable cox regression that was
performed to determine significant predictors of LTFU.
The sex and age variables were included into the model as
known priori. A p-value of 0.05 or less was considered to
be statistically significant.
Ethical and legal considerations
All the participants in the MNPC cohort signed
informed consent to be included in the PV surveillance
study. Participants that were less than 18 years of age
were required to provide verbal assent and their legal
representative or guardian gave written informed con-
sent for participation in the study. Ethical approval for
this study was received from the University of Pretoria’s
Faculty of Health Sciences Research Ethics Committee.
Results
Description of the Tshepang pharmacovigilance cohort
Overall, 1117 patients were enrolled into the MNPC PV
cohort at Tshepang sentinel site, from September 2004
to June 2012. Fifty-three percent (595/1117) of the
patients were included in the current study. The other
522 (47 %) patients were excluded either because the
patient file could not be retrieved from the clinic records
(n = 491) or there was either an unknown date of ART
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initiation or unknown date of last clinic visit (n = 31)
(Fig. 1). There were no significant differences in the
distribution of sex (p = 0.334) and age (p = 0.891) vari-
ables in patients included in the study when compared
to those excluded from the analysis.
Among the patients included in the analysis, 15.3 %
(91/595) were still in care at Tshepang clinic, 61.3 %
(365/595) had been down-referred or transferred to
another clinic and 23.4 % (139/595) were LTFU. Of the
patients who were LTFU, 11.5 % (16/139) returned to
care after missing more than 180 days of clinic appoint-
ments and 10.6 % (63/139) were known to have died (Fig. 1).
The proportion of patients that died was higher in patients
that never returned to care (48.8 %) compared to those that
returned to care (18.8 %), (p = 0.023). (Refer to Fig. 1). The
median time in care for patients that were down referred
or transferred was 614 days (Interquartile Range (IQR):
416 to 843 days). The median time in care for patients
that are in care was 1205 days (IQR: 851 to 1604 days)
and median time in care for those patients that were
LTFU was 482 days (IQR: 251 to 1046 days).
Baseline demographic characteristics of study participants
Table 1 shows the baseline demographic and clinical
characteristics of the 595 patients that were included in
the study. The median age at ART initiation was 35.9 years
(IQR: 30.1- 43.5), and 65.5 % were women. At ART initi-
ation the majority of the patients had achieved secondary
level of education (60.6 %), were unemployed (75.5 %),
and had no committed partner (80.3 %). Baseline
demographic characteristics of patients that were LTFU
versus those that remained in care were similar except
with regards to employment status. A lower proportion of
the patients that remained in care were unemployed
(73.6 %) compared to the patients that were LTFU
(81.0 %) (p = 0.028) (Table 1).
Incidence of LTFU
The data of the 595 patients that we included in the study
represented 1280 person-years of follow up time. The
overall incidence rate of LTFU in the cohort was esti-
mated to be 109 per 1000 person-years (95 % Confidence
Interval (CI): 92–128). Among the patients LTFU, the
median duration on follow up was 21.5 months (inter-
quartile range (IQR): 12.9 - 34.7). Patient retention in care
was 81.8 % at 2 years and 54.7 % at 5 years in the cohort
as illustrated in Fig. 2.
Approximately 40 % (57/139) of the patients that
became lost to follow up were lost within the first year
of being initiated on ART. The absolute number of pa-
tients that were LTFU with each year on ART appeared
to decrease over time. However, on further analysis, we
found that the incidence rate of LTFU was 103 per 1000
person-years in the first year on ART and increased to
405 per 1000 person-years in the eighth year of taking
ART (Fig. 3).
Alive (n=63)
Patients enrolled into the Tshepang sentinel site 
Pharmacovigilance cohort (N=1117)
Loss to follow-up (n=139)
Transferred/down referred to another 
clinic (n=365)
Patients included in study (N=595)
Returned to care (n=16) Never returned to care (n=123) 
Alive (n=13) Dead (n=3) Dead (n=60) 
Still in care at Tshepang (n=91) 
Unknown date of ART initiation or last 
clinic visit (n=31)
Patient files not found (n=491)
Fig. 1 A flow diagram describing the patients enrolled into the Tshepang Pharmacovigilance cohort and their various outcomes, 2004–2012
Mberi et al. BMC Health Services Research  (2015) 15:259 Page 4 of 11
Clinical characteristics of the participants
The baseline patient weight was lower (median = 55.6 kg)
among patients who became LTFU, compared the baseline
weight (median = 57.2 kg) of patients who remained in
care (p < 0.001). The median patient weight increased
from 55.6 kg at baseline to 58.5 kg at the last recorded
weight among patients LTFU (p < 0.001), and from 57.2 kg
at baseline to 65.2 kg at the last clinic visit among patients
who remained in care (p < 0.001). Median of the last
known weight was lower in patients that were LTFU
(58.5 kg) than those that were not (65.2 kg) (p < 0.001)
(Table 2).
Baseline CD4 cell counts were lower among patients
who later became LTFU (median = 79 cells/ml, IQR:
30–146), compared to cell counts for patients who
remained in care (median = 87cells/ml, IQR: 36–150)
(p < 0.001) (Table 2). This was the same for last known
CD4 count where median CD4 count was significantly
lower in patients that were LTFU (median = 197.5, IQR:
113.8-347.0 cells/ml) than in those that were not LTFU
(median = 275.0, IQR: 177.5-389.2cells/ml). The median
CD4 counts increased from 79 cells/ml at baseline to
198 cells/ml at the last measured count among patients
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Fig. 2 Kaplan Meier graph showing the probability of remaining in care with time, Tshepang Pharmacovigilance cohort, 2004–2012
Table 1 Baseline demographic characteristics of patients included in study, Tshepang Pharmacovigilance cohort, 2004-2012
Variable Total LTFU In care χ2
N % n (%) n % p-value
Sex Female 390 (65.5) 87 (62.6) 303 (66.5) 0.402
Age at ART initiation (years) ≥ 45 years 129 (21.7) 30 (21.6) 99 (21.7) 0.113
≥ 30 and < 45 320 (53.8) 66 (47.5) 254 (55.7)
< 30 146 (24.5) 43 (30.9) 103 (22.6)
Racial grouping Black 512 (99.4) 100 (99.0) 412 (99.5) 0.548
(80 missing) Other 3 (0.6) 1 (1.0) 2 (0.5)
Education level None 34 (6.2) 7 (5.4) 27 (6.5) 0.110
(50 missing) Primary 153 (28.1) 34 (26.2) 119 (28.7)
Secondary 330 (60.6) 77 (59.2) 253 (60.9)
Tertiary 28 (5.1) 12 (9.2) 16 (3.9)
Employment status Employed 141 (24.2) 24 (17.5) 117 (26.2) 0.028
(14 missing) Unemployed 439 (75.3) 111 (81.0) 328 (73.6)
Self employed 3 (0.5) 2 (1.5) 1 (0.2)
Live-in partner Present 115 (19.7) 19 (14.0) 96 (21.4) 0.057
(10 missing) Absent 472 (80.3) 117 (86.0) 353 (78.6)
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baseline to 275 cells/ml at last measured count among
patients who remained in care (p < 0.001) (Table 2).
There was a lower proportion (121/135, 90 %) of
patients with CD4 count <200 cells/ml at baseline mea-
surement in patients that became LTFU than in those
that were not LTFU (427/452, 94.4 %) (p = 0.048). There
was, however, a higher proportion (60/118, 50.8 %)
of patients that had a last known CD4 count <200
(p < 0.001) in patients that were LTFU (60/119, 50.4 %)
when compared patients that were not LTFU (43/441,
32.4 %) (Fig. 4).
Most (62 %) patients were in WHO clinical stages
three or four prior to ART initiation. At the initiation of
ART, 63 % (80/127) of the patients that became LTFU
were in WHO clinical stages 3 or 4, compared to
61 % (255/418) of the patients that remained in care
(p = 0.190). However, at last clinic visit before outcome,
53.6 % (67/125) of patients that were LTFU had a WHO
clinical stage 3 or 4, compared to 26.0 % (100/384) of
the patients that remained in care (p < 0.001) (Fig. 4).
Sixty-one percent (61/100) of the patients that were
LTFU had an undetectable VL when it was first mea-
sured after initiating ART compared to 81.9 % (353/431)
of patients that remained in care (p < 0.001). At last
recorded VL measurement, 43.8 % (50/114) of the pa-
tients that were LTFU had an undetectable VL compared
to 85.8 % (376/438) of patients that remained in care
(p < 0.001). The findings show a decrease in the percent-
age of patients that had undetectable VL levels among
patients that were LTFU (p = 0.012), while revealing no
significant changes in the percentage of patients with
undetectable VL among patients who remained in care
(p = 0.114).
Treatment and related characteristics
Most patients in the cohort (581/591, 98.3 %) were initi-
ated on stavudine (d4t) containing regimens. Almost
18 % (100/568) of patients reported that they drank alco-
hol at the time of ART initiation. A total of 316/567
(55.7 %) patients in the cohort have experienced at least
one ART related adverse event. There were no differ-
ences in the proportions of patients who were initiated
on a stavudine containing regimen (p = 0.466), drank
alcohol at baseline (p = 0.852) or experienced an ART
related adverse event during treatment (p = 0.057), when
comparing patients that were LTFU to those that
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Fig. 3 Number of patients and the period incidence of LTFU with each year of taking ART, Tshepang Pharmacovigilance cohort, 2004–2012
Table 2 Characteristics of patients that were LTFU compared to those that were not LTFU, Tshepang Pharmacovigilance cohort, 2004-2012
Variable LTFU In care Rank sum p-value
Median IQR Median IQR
Baseline weight (kg) 55.6 46.8 - 62.6 57.2 51.0 - 66.0 <0.001
Last known weight (kg) 58.5 48.5 - 66.7 65.2 56.8 - 73.3 <0.001
Baseline CD4 count (cells/ml) 79.0 30.0 - 146.0 87.0 36.0 - 150.0 <0.001
Last known CD4 count (cells/ml) 197.5 113.8 - 347.0 275.0 177.5 - 389.2 <0.001
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Close to a quarter (74/316, 23.4 %) of patients that
had adverse events experienced more than one adverse
event. The most commonly reported adverse events
included peripheral neuropathy (165/316, 52.2 %), lipo-
dystrophy (121/316, 38.3 %) and hyperlactaemia (83/316,
26.3 %). Other ART related adverse events that were
experienced included anaemia, various dermatological
adverse events, central nervous system adverse events,
diarrhoea and vomiting, lipid abnormalities and hepa-
titis. The proportion of LTFU patients who experienced
peripheral neuropathy was 28.1 % (39/139), along with
7.2 % (11/139) who experienced lipodystrophy, 9.4 %
(13/139) experienced hyperlactataemia, and 31.6 %
(6/139) experienced other adverse events (Table 4).
Factors associated with LTFU
In the multivariable Cox regression model, the risk fac-
tors that were independently associated (p < 0.05) with
becoming LTFU were not having a committed partner
(aHR = 2.88, 95 % CI 1.19-6.97), being self-employed
(aHR = 13.92, 95 % CI: 2.81-69.06), having a baseline
CD4 count > 200 cells/ml (aHR = 3.81, 95 % CI: 1.85-7.85),
having a history of an ART related adverse event prior to
outcome (aHR = 0.61, 95 % CI: 0.38-0.99), having a
last known viral load that was detectable (aHR = 3.60,
95 % CI: 1.98-6.52), and having a last known WHO clinical
stage three or four (aHR = 2.00, 95 % CI: 1.22-3.27),
(Table 5). Education level and alcohol intake status at ART
initiation, regimens on which patients were initiated and
baseline WHO clinical staging were not associated with be-
coming LTFU on univariate analysis and were not included
in the multivariable regression model (Table 5).
Discussion
We found a progressive increase in the incidence of
LTFU patients with each year after initiation of ART: the
patient retention rate was 82 % after 2 years and 55 %
after 5 years. This finding is similar to other studies
done in sub-Saharan Africa [8–10]. It is, however,
important to keep in mind that different definitions of
Fig. 4 Comparing CD4 counts, viral load levels and clinical staging in patients that were LTFU and that are in care, Tshepang Pharmacovigilance
cohort, 2004–2012
Table 3 ART and adverse event related characteristics of patients that were LTFU compared to those that remained in care, Tshepang
Pharmacovigilance cohort, 2004-2012
Variable Total LTFU In care χ2
N % n (%) n % p - value
Initiating regimen d4t containing* 581 98.3 443 98.0 138 99.3 0.466
4missing Other 10 1.7 9 2.00 139 0.7
Alcohol No 468 82.4 107 82.95 361 82.2 0.852
27 missing Yes 100 17.6 22 17.05 78 7.8
Adverse events No 251 44.3 67 51.5 184 42.1 0.057
28 missing Yes 316 55.7 63 48.5 253 57.9
*d4t – stavudine
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LTFU may have been used in these studies. Due to
limited research, we compare our study findings to the
available research literature, bearing in mind that some
of these study findings may or may not have been diffe-
rent, if our definition of LTFU would have been applied
to their analysis. Our retention rate at 2 years gives the
impression that our retention rates are at higher end of
the rates that have been reported in some sub-Saharan
ART programs (range from 24 to 77 % at 2 years) [8].
South Africa has a goal that at least 70 % of patients
that are initiated on ART are alive and on treatment
5 years after ART initiation [11]. Though we appear to
have comparatively better programmatic success in
retaining patients in care at 2 years after ART initiation
when compared to other sub-Saharan programs, we are
not achieving this 70 % retention target at 5 years after
ART initiation, and more effort is needed to improve
patient retention in care at 5 years after ART initiation.
Our study, like other studies that have shown that be-
ing single is a risk factor for becoming LTFU [20], found
that patients that did not have a committed partner had
a higher risk of becoming LTFU. This suggests that
having a committed primary relationship is protective
against being LTFU. In our study we found that 80 % of
patients did not have committed primary relationships.
It is therefore important that other systems and
Table 4 ART related adverse events experienced by patients and proportions that had adverse events in patients that were LTFU
versus those still in care, Tshepang Pharmacovigilance cohort, 2004-2012
Adverse event Total LTFU In Care
N % n (%) n %
Peripheral Neuropathy 165 52.2 39 28.1 126 21.2
Lipodystrophy 121 38.3 11 7.2 110 24.1
Hyperlactateaemia 83 26.3 13 9.4 70 15.4
*Others 19 6.0 6 4.3 13 2.9
*Others include anaemia, various dermatological adverse events, Central nervous system adverse events, diarrhoea and vomiting, lipid abnormalities and
hepatititis
Table 5 Cox Regression analysis to determine factors associated with LTFU, Tshepang Pharmacovigilance cohort, 2004-2012
Characteristic Univariate analysis Multivariate Analysis
HR 95 % CI P value aHR 95 % CI P value
Age at ART ≥ 45 Ref* Ref*
Initiation ≥ 30 and < 45 0.77 0.50 - 1.19 0.240 0.71 0.37 - 1.37 0.310
< 30 0.94 0.59 - 1.51 0.810 0.58 0.28 - 1.21 0.144
Partner status Present Ref* Ref*
Absent 1.75 1.08 - 2.84 0.024 2.88 1.19 - 6.97 0.019
Employment Employed Ref* Ref*
Status Self employed 7.18 1.69 - 30.54 0.008 13.92 2.81 - 69.06 0.001
Unemployed 1.57 1.01 - 2.44 0.045 1.75 0.86 - 3.56 0.123
Adverse events No Ref* Ref*
Yes 0.49 0.34 - 0.70 <0.001 0.61 0.38 - 0.99 0.044
Baseline CD4 CD4≤ 200 Ref* Ref*
Count CD4 > 200 2.47 1.42 - 4.31 0.001 3.81 1.85 - 7.85 < 0.001
First VL level Undetectable VL Ref* Ref*
after ART Detectable VL 1.81 1.21 - 2.72 0.004 1.00 0.58 - 1.73 0.998
Last known CD4 CD4≤ 200 Ref* Ref*
Count CD4 > 200 0.42 0.29 - 0.60 < 0.001 0.88 0.51 - 1.53 0.651
Last known VL Undetectable VL Ref* Ref*
Level Detectable VL 3.20 2.20 - 4.67 < 0.001 3.60 1.98 - 6.52 < 0.001
Last known WHO Stage 1 or 2 Ref* Ref*
clinical stage Stage 3 or4 3.20 2.24 - 4.57 < 0.001 2.00 1.22 - 3.27 0.006
*Ref - Reference category
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programs that lower the rates of LTFU be employed. In-
tegrated patient care, community based adherence sup-
port programs, active outreach to patients, the
availability of adherence support services as well as facil-
ity and community based patient adherence groups on
ART have been found to lead to lower rates of LTFU
[12, 14–16, 19, 20]. These findings are well in support of
the South African government’s call for integrated pa-
tient care and the nationwide rolling out of adherence
clubs/groups. It is also important for health facilities to
investigate facility specific factors that can impact LTFU
rates and implement programs that are tailored specific-
ally to reduce LTFU in their unique settings [19]. Though
other studies have also shown that young age, being male
and illiteracy are risk factors for becoming LTFU, an asso-
ciation between age, sex or level of education and becom-
ing LTFU was not found our study [9, 17, 20].
The benefits of taking ART were clearly identified: we
found that there were significant increases in weight as
well as in immune function (evidenced by increasing
CD4 cell counts) from the time of ART initiation till
the last known measurements both in patients that
were LTFU and in those that remained in care. Our
findings showed that patients that became LTFU had
significantly lower weight and CD4 cell count measure-
ments both at ART initiation and at last known meas-
urement. However, patient weight was not associated
with becoming LTFU.
There have been varying findings with regards to the
association between baseline CD4 cell count and LTFU,
with some studies showing that patients that had CD4
counts between 301 cells/ml and 350 cells/ml had a
lower risk of becoming LTFU than those with CD4
counts < 200 cells/ml [13], while others showed that
higher baseline CD4 cell count was associated with a
higher risk of LTFU [12, 20, 21]. Our findings showed
that patients that had a CD4 cell count of > 200 cells/ml
at ART initiation were at a higher risk of becoming
LTFU. This finding could possibly be explained by the
fact that patients with a high CD4 cell count generally
do not have the typical clinical symptoms of advanced
HIV disease and thus, may not perceive the benefits of
the strict patient follow-up schedule. However, we did
not find any association between baseline WHO clinical
staging and LTFU to further support this explanation.
That we did not find any significant association between
baseline WHO staging and LTFU was unlike other studies
[17]. This could be explained by the fact that eligibility
criteria for ART initiation may be based only on WHO
staging in resource constrained countries, and may
account for the variable study findings regarding the
association between LTFU and WHO clinical staging.
The use of WHO clinical staging as an ART eligibility
criteria, may not necessarily correlate with immune
status (CD4 count) or actual disease progress, especially
where diagnostic tests for AIDS defining conditions are
not readily available.
In our study we were able to demonstrate that patients
that were not virologically suppressed (VL > 50 copies/ml)
at last clinic visit had a three times higher risk of
becoming LTFU than those that had a suppressed VL.
Similarly, patients who had advanced clinical disease at
last clinic visit (WHO clinical stage three or four) were
twice as likely to become LTFU. Similar findings have
been reported in other studies [17, 18]. It is important for
measures to be put in place that improve retention rates
among patients whose viral loads remain high and/or who
continue to display advanced clinical stages of HIV
disease, despite taking ART.
There is limited literature on the association between
ART adverse events and LTFU. Just over half (56 %) of
our cohort had a history of at least one ART related
adverse event since ART initiation. Less than a quarter
of the patients who reported experiencing each of the
common ART related adverse event became LTFU. We
would have expected that patients experiencing adverse
events would likely be discouraged from taking their
ART. However we found that these patients had a lower
risk of becoming LTFU when compared to patients that
had not had ART related adverse events. This result may
possibly be due to the perception that patients have of
their health status, but further investigation is necessary.
The MNPC is the only structured surveillance cohort
that has been set up by the South African National
Department of Health to follow up patients that have
been initiated on ART. As such, the cohort is the
evidence base which provides insight into different as-
pects of the National ART program. Our study did have
limitations that should be taken into account when
interpreting the findings. Firstly, we only analysed about
53 % of the patients that were enrolled into the PV
surveillance cohort during the period of the study. This
could have possibly introduced some selection bias into
the study and could have led to an over- or under-
estimation of the true incidence of LTFU in our study.
We, however, found no significant differences in demo-
graphic characteristics when we compared the patients
that we included in the study and those that were
excluded. Secondly, we were unable to obtain the date of
death for some of the patients that died after being
LTFU, and thus were not able to confirm whether the
patients died 180 days or more after the last clinic
appointment. It is therefore possible that some of these
patients were misclassified as LTFU, resulting in an
over-estimation of the true incidence of LTFU. Thirdly,
we assumed that all the patients that were transferred
from Tshepang clinic to other ART clinics were still in
care at the time of censoring. It is possible that some of
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these patients became LTFU after being transferred,
leading to an under-estimation of the rate of LTFU in
our study. Lastly, it is also likely that some of the
patients that we classified as LTFU could have self-
transferred and continued ART at other sites without
notifying Tshepang clinic. This could have led to an
over-estimation of the incidence rate of LTFU in our
study. Despite these limitations, we believe that our
study findings provide an important insight into the
magnitude and the factors related to LTFU among
patients on ART.
Conclusions
Our study shows that LFTU after ART initiation is
high in South Africa, although patient retention in care
at 2 years after ART initiation appears to be higher than
in some ART programs in sub-Saharan Africa. The inci-
dence rate of LTFU increases with additional years on
ART, and patient retention at 5 years is much lower than
the target of at least 70 % that is in the South African
NSP on HIV, STI’s and TB (2012–2016). Our findings
will help ART clinicians to recognize patients that
require additional support to remain in care, such as
patients with higher CD4 cell counts (> 200 cells/ml)
at baseline, patients who do not have committed
partners and patients who continue to have detectable
VL (> 50 copies/ml) or advance clinical disease (WHO
clinical stages 3 or 4) after ART initiation. These
patients require additional support such as community
based adherence support programs and the use of
reminder tools, which have been shown to reduce LTFU
in similar settings. There is also a need to intensify
surveillance activities in order to allow the country to
accurately monitor rates of, and reasons for, LTFU in
patients that are on ART.
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